Mature results from three large controlled studies with raltitrexed ('Tomudex')
1998

Study Results of Raltitrexed in Colorectal Cancer

Sample size: 1500 publication Evidence: moderate

Author Information

Author(s): D Cunningham

Primary Institution: The Royal Marsden Hospital

Hypothesis

Raltitrexed is an effective alternative to 5-FU-based therapy in patients with advanced colorectal cancer.

Conclusion

Raltitrexed shows similar efficacy to 5-FU with a more predictable toxicity profile.

Supporting Evidence

  • Raltitrexed had an overall objective response rate of 26%.
  • Median survival for raltitrexed was 11.2 months.
  • Patients receiving raltitrexed experienced less mucositis compared to those on 5-FU.
  • Raltitrexed's toxicity profile is more predictable than that of 5-FU.
  • Cost of raltitrexed therapy is similar to that of the Mayo regimen.

Takeaway

Raltitrexed is a new cancer drug that works as well as an older drug called 5-FU but causes fewer side effects.

Methodology

Three phase III clinical trials compared raltitrexed with 5-FU plus leucovorin in patients with advanced colorectal cancer.

Potential Biases

Investigator bias may have affected treatment continuation decisions.

Limitations

The 4.0 mg m-2 dosage arm was discontinued due to toxicity, which may have influenced results.

Participant Demographics

Patients were primarily adults with advanced colorectal cancer, with a mean age around 61 years.

Statistical Information

P-Value

0.01

Confidence Interval

95% CI 9.6-13.1 months

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication